A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Alisertib (Primary) ; Bortezomib (Primary) ; Rituximab
- Indications Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 06 Dec 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Dec 2017.
- 07 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov record.
- 08 Oct 2012 New trial record